FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

Artificial intelligence has bounded into the mainstream, into personal lives, classroom assignments and work meetings — so it should be no surprise to find it in doctors’ offices and emergency ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

March is Ovarian Cancer Awareness Month - but one local survivor has called for greater understanding of the condition which ...

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to ca ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...